Total operating revenues at Branford-based Neurogen Corp. dropped to zero in the fourth quarter of 2007, down from more than $2 million during the same period in 2006.
The company also reported a net loss of $14.9 million in Q4 2007 compared to $16 million in 2006. The company’s year-end net loss rose to $55.7 million in 2007 from $53.8 million the year before. Neurogen’s operating loss eased up slightly at $15.3 million in the fourth quarter of 2007 from $17 million at the same time in 2006.
“While 2007 marked a year of solid progress, I expect 2008 to be a year of both new exploration and the realization of important clinical results,” said Stephen R. Davis, president and CEO of Neurogen, in a statement.
